MAP2K1

Across TCGA pan-cancer cohorts, MAP2K1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP2K1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MAP2K1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP2K1 expression acts as an unfavorable survival marker.

LIHC, SKCM, and ESCA are the cancer types where MAP2K1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.114	0.786	<.001	36	view →
SKCM	DFS	Median	II,III,IV	0.344	0.581	.003	19	view →
ESCA	DFS	Median	All	0.098	0.533	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP2K1–LIHC (OS)

Open the LIHC breakdown →